Effect of Rifaximin and a Multi-Strain Probiotic on the Intestinal Microbiome and Cardiovascular Risk Indicators in Patients with Coronary Heart Disease
Aim. To assess the effect of rifaximin and a multi-strain probiotic on the intestinal microbiome and the indicators of cardiovascular risk in patients with coronary heart disease (CHD).Materials and methods. A study conducted during the 2016–2019 period included 120 people over 50 years old divided...
Saved in:
Main Authors: | E. A. Kashukh, E. A. Poluektova, A. V. Kudryavtseva, G. S. Krasnov, V. I. Kazey, P. D. Sobolev, P. V. Gremyakova, V. T. Ivashkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2019-09-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/396 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interrelationships of the Intestinal Microbiome, Trimethylamine N-Oxide and Lipopolysaccharide-Binding Protein with Crohn’s Disease Activity
by: Yelena Laryushina, et al.
Published: (2024-12-01) -
Efficacy of rifaximin in the treatment of chronic relapsing diverticulitis
by: S. I. Achkasov, et al.
Published: (2012-04-01) -
Russian Non-Interventional Study of the Efficacy and Tolerability of Rifaximin-α Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice
by: O. S. Shifrin, et al.
Published: (2020-04-01) -
Practical Recommendation of the Scientific Сommunity for Human Microbiome Research (CHMR) and the Russian Gastroenterological Association (RGA) on Small Intestinal Bacterial Overgrowth in Adults
by: V. T. Ivashkin, et al.
Published: (2022-09-01) -
Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial
by: Do Seon Song, et al.
Published: (2025-01-01)